Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists
- 2.3k Downloads
We characterized undifferentiated (UN) and three differentiation conditions of the SH-SY5Y neuroblastoma cell line for phenotypic markers of dopaminergic cells, sensitivity to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridinium ion (MPP), the requirement to utilize the dopamine (DA) transporter (DAT) for MPP toxicity, and the neuroprotective effects of pramipexole. Cells were differentiated with retinoic acid (RA), 12-O-tetradecanoly-phorbol-13-acetate (TPA), and RA followed by TPA (RA/TPA). RA/TPA treated cells exhibited the highest levels of tyrosine hydroxylase and DAT but lower levels of vesicular monoamine transporter. The kinetics of [3H]DA uptake and [3H]MPP uptake to DAT in RA/TPA differentiated cells were similar to that of rat and mouse caudate-putamen synaptosomes. RA/TPA differentiated cells evidenced high sensitivity to the neurotoxic effects of MPP (0.03 to 3.0 mM), and the neurotoxic effects of MPP were blocked with the DAT inhibitor 1-(2-[bis(4-fluorophenyl)methoxy]ethyl)-4-(3-phenylpropyl)piperazine (GBR 12909). DA-induced cell death was not more sensitive in RA vs RA/TPA differentiated cells and was not inhibited by transporter inhibitors. RA/TPA differentiated cells exhibited 3- fold and 6-fold higher levels, respectively, of DA D2 and D3 receptors than UN or RA differentiated cells. Pretreatment with pramipexole was protective against MPP in the RA/TPA differentiated cells but not in undifferentiated or RA differentiated cells. The neuroprotective effect of pramipexole was concentration-dependent and dopamine D2/D3 receptor dependent. In contrast, protection by pramipexole against DA was not DA receptor dependent. Further characterization of the neuroprotective effects of DA agonists in this model system can provide unique information about DA receptor dependent and independent mechanisms of neuroprotection.
KeywordsParkinson's disease D2 Receptor D3 Receptor MPP Dopamine transporter Pramipexole
Unable to display preview. Download preview PDF.
- Burns RS, CC Chiueh, SP Markey, MH Ebert, DM Jacobowitz and IJ Kopin (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra byN-methyl-4- phenyl-1,2,3,6-tetrahydropyridine.Proc. Natl. Acad. Sci. USA 80, 4546–4550.PubMedCrossRefGoogle Scholar
- Carvey PM and ZD Ling (1997) The case for neuroprotection with dopamine agonistsClin. Neuropharmacol. 20 [Suppl.], S8-S21.Google Scholar
- Cohen G and P, Werner (1994) Free radicals, oxidative stress and neurodegeneration, inNeurodegenerative Disorders (Calne DB, Ed.) (WB Saunders, Philadelphia, PA), pp. 139–162.Google Scholar
- Dickinson SD, J Sabeti, GA Larson, K Giardina, M Rubinstein, MA Kelly, DK Grandy, MJ Low, GA Gerhardt and NR Zahniser (1999) Dopamine D2 receptor-deficient mice exhibit decreased dopamine transporter function but no changes in dopamine release in dorsal striatum.J. Neurochem. 72, 148–156.PubMedCrossRefGoogle Scholar
- Eshleman AJ, K Wolfrum, DC Mash, K Christensen and A Janowsky (2001) Drug interactions with the dopamine transporter in cryopreserved human caudate.J. Pharm. Exp. Ther. 296, 442–449.Google Scholar
- Gobert A, JM Rivet, V Audinot, L Cistarelli, M Spedding, J Vian, JL Peglion and MJ Millan (1995) Functional correlates of dopamine D3 receptor activation in the ratin vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and “silent” D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways.J. Phar. Exp. Ther. 275, 899–913.Google Scholar
- Kitamura Y, T Kosaka, JI Kakimura, Y Matsuoka, Y Kohno, Y Nomura and T Taniguchi (1998) Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells.Mol. Pharmacol. 54, 1046–1054.PubMedGoogle Scholar
- Matecka D, RB Rothman, L Radesca, BR de Costa, CM Dersch, JS Partilla, A Pert, JR Glowa, FH Wojnicki and KC Rice (1996) Development of novel, potent, and selective dopamine reuptake inhibitors through alteration of the piperazine ring of 1-[2-(diphenylmethoxy)ethyl]-and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909).J. Med. Chem. 39, 4704–4716.PubMedCrossRefGoogle Scholar
- McNaught KS, U Thull, PA Carrupt, C Altomare, S Cellamare, A Carotti, B Testa, P Jenner and CD Marsden (1996) Nigral cell loss produced by infusion of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.Neurodegeneration 5, 265–274.PubMedCrossRefGoogle Scholar
- Przedborski S, V Jackson-Lewis, R Djaldetti, G Liberatore, M Vila, S Vukosavic and G, Almer (2000) The parkinsonian toxin MPTP:action and mechanism.Restorative Neurol. Neurosci. 16, 135–142.Google Scholar
- Veech GA, J Dennis, PM Keeney, CP Fall, RH Swerdlow, WD Parker Jr and JP Bennett Jr (2000) Disrupted mitochondrial electron transport function increases expression of anti-apoptotic bcl-2 and bcl-X(L) proteins in SH-SY5Y neuroblastoma and in Parkinson disease cybrid cells through oxidative stress.J. Neurosci. Res. 61, 693–700.PubMedCrossRefGoogle Scholar